Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
- PMID: 17683579
- PMCID: PMC1988829
- DOI: 10.1186/1471-2407-7-149
Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Abstract
Background: Signal transducer and activator of transcription 3 (STAT3) is usually constitutively activated in a variety of malignancies. Therefore, STAT3 may be a promising target for treatment of tumor cells. To explore the possibility of a double-stranded decoy oligodeoxynucleotide (ODN) targeted blocking STAT3 over-activated tumor cells, we, here, evaluate the efficacy of STAT3 decoy ODN on human lung cancer cells in vitro and in vivo.
Methods: A STAT3 decoy ODN was transfected into A549 lung cancer cell line in vitro by using lipofectamine. The flow cytometry and fluorescent microscopy were used to detect the transfection efficiency and the sub-cellular localization of STAT3 decoy ODN in A549 cells. Cell proliferation was determined by counting cell numbers and [3H]-thymidine uptake. Cell apoptosis was examined with Annexin V and propidum iodide by flow cytometry. The expression levels of STAT3 target genes were identified by RT-PCR and immunoblot. For in vivo experiment, A549 lung carcinoma-nude mice xenograft was used as a model to examine the effect of the STAT3 decoy by intratumoral injection. At the end of treatment, TUNEL and immunohistochemistry were used to examine the apoptosis and the expression levels of bcl-xl and cyclin D1 in tumor tissues.
Results: STAT3 decoy ODN was effectively transfected into A549 lung cancer cells and mainly located in nucleus. STAT3-decoy ODN significantly induced apoptosis and reduced [3H]-thymidine incorporation of A549 cells as well as down-regulated STAT3-target genes in vitro. STAT3 decoy ODN also dramatically inhibited the lung tumor growth in xenografted nude mice and decreased gene expression of bcl-xl and cyclin D1.
Conclusion: STAT3 decoy ODN significantly suppressed lung cancer cells in vitro and in vivo, indicating that STAT3 decoy ODN may be a potential therapeutic approach for treatment of lung cancer.
Figures





Similar articles
-
STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes.Oncol Rep. 2007 Jun;17(6):1377-82. Oncol Rep. 2007. PMID: 17487394
-
Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo.In Vivo. 2009 Mar-Apr;23(2):237-43. In Vivo. 2009. PMID: 19414409
-
Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.Clin Cancer Res. 2008 Oct 15;14(20):6432-9. doi: 10.1158/1078-0432.CCR-07-4401. Clin Cancer Res. 2008. PMID: 18927282
-
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.Ann N Y Acad Sci. 2006 Dec;1091:151-69. doi: 10.1196/annals.1378.063. Ann N Y Acad Sci. 2006. PMID: 17341611 Review.
-
Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis.Mol Carcinog. 2007 Aug;46(8):725-31. doi: 10.1002/mc.20342. Mol Carcinog. 2007. PMID: 17610223 Review.
Cited by
-
Role of STAT3 in lung cancer.JAKSTAT. 2015 Jan 20;3(4):e999503. doi: 10.1080/21623996.2014.999503. eCollection 2014. JAKSTAT. 2015. PMID: 26413424 Free PMC article. Review.
-
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.Cancer Discov. 2012 Aug;2(8):694-705. doi: 10.1158/2159-8290.CD-12-0191. Epub 2012 Jun 20. Cancer Discov. 2012. PMID: 22719020 Free PMC article. Clinical Trial.
-
Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.Cell Death Dis. 2016 Oct 13;7(10):e2421. doi: 10.1038/cddis.2016.305. Cell Death Dis. 2016. Retraction in: Cell Death Dis. 2021 Mar 15;12(3):281. doi: 10.1038/s41419-021-03529-7. PMID: 27735939 Free PMC article. Retracted.
-
Increase of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro.Exp Ther Med. 2012 Feb;3(2):255-260. doi: 10.3892/etm.2011.381. Epub 2011 Nov 16. Exp Ther Med. 2012. PMID: 22969878 Free PMC article.
-
Portrait of inflammatory response to ionizing radiation treatment.J Inflamm (Lond). 2015 Feb 18;12:14. doi: 10.1186/s12950-015-0058-3. eCollection 2015. J Inflamm (Lond). 2015. PMID: 25705130 Free PMC article.
References
-
- Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous